Short answer
Insmed Incorporated (INSM) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Insmed announced third-quarter results for the period ended September 30, 2026.
Insmed Incorporated 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Insmed announced third-quarter results for the period ended September 30, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
- Exhibit 99.2 contains investor presentation materials for the earnings conference call
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 revenue $524.4M, up 268% year over year, led by BRINSUPRI’s U.S. launch
- BRINSUPRI revenue $400.1M, up 29% sequentially, supporting raised 2026 guidance to $1.35B-$1.4B
- ARIKAYCE revenue $124.4M, up 9% year over year, with 2026 guidance raised to $460M-$470M
- Net loss narrowed to $100.3M, or $0.46 per share, from $370.0M, or $1.75 per share
- Japan launch expands BRINSUPRI access, while ARIKAYCE Priority Review targets potential label expansion on January 28, 2027
Item EX-99.2 · Exhibit EX-99.2
- Q3 revenue $524.4M, up from $142.3M, driven by BRINSUPRI’s $400.1M launch performance
- BRINSUPRI full-year 2026 guidance raised to $1.35B-$1.4B from $1.25B-$1.4B
- ARIKAYCE revenue $124.4M, up 9% year over year, with full-year guidance raised to $460M-$470M
- FDA priority review targets January 28, 2027 for ARIKAYCE label expansion, potentially expanding U.S. and Japan addressable market to >200K patients
- Operating loss narrowed to $89.4M from $366.0M, while cash, equivalents and marketable securities totaled approximately $1.1B
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Insmed Incorporated 8-K filings
Get the next INSM 8-K as it lands
Follow INSM for push alerts, or ask the research agent what this filing means.